ALSO NOTED: Sirtris, NCI collaborate on cancer models; Kylin expands in Indiana; and much more...

> Sirtris announced a collaboration with the National Cancer Institute to its enzyme activators in cancer models. Report

> Kylin Therapeutics in Indiana has been expanding with the help of funds provided by the state's Economic Development Corp. Report

> The Los Angeles Times reports on the growing profitability of the HIV drug sector, which has been particularly beneficial to Gilead Sciences. Article

> Sirion Therapeutics has licensed rights to develop eye therapies using a anti-inflammatory agent developed by Bridge Pharma. Release

> LA-based ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., MBA has taken on the full-time position of president and CEO. Release

> Eurand has been granted a priority review by the FDA for Zentase--EUR-1008. Release

> Forest Laboratories and Cypress Biosciences say the FDA has agreed to review their NDA application for milnacipran, a treatment for fibromyalgia. Report

> Medical device makers got some supreme protection yesterday. The highest court raised a partial shield against lawsuits, saying that devices that passed the FDA's most stringent premarketing review are exempt from consumer lawsuits. Report

> A Nobel Prize-winning biologist says that researchers are no closer to developing a vaccine against HIV than they were 20 years ago, when the scientific quest began. Report

> Can a vaccine control high blood pressure? Report

> There's growing evidence around the U.S. that the flu jab offers only marginal protection against the seasonal ailment. Report

> In 2007, drugmakers jacked prescription prices up 7.8 percent. Report

And Finally…The CDC says the U.S. has made enormous efforts to prepare for a health crisis, like a flu pandemic, but cautions that an enormous amount of work remains to be done. Article

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.